Mo [Mo T] Human Hair Cell Leukemia

John Moore, the source patient of this cell line (33 years old at the time of sampling), sued David Gold and the University of California because they applied for a patent on the Mo cell line without John Moore's permission. Although Moore's claim of ownership was rejected, his doctor was considered to have violated his fiduciary duty. Through mycoplasma detection in this library. Through STR detection in this library.

Morphology lymphoblasts; Suspension growth

Culture media and additives/Complete Growth Medium and Culture Conditions:

90% 1640 (MD0200)+10% fetal bovine serum (SD0200)+G/A (SD0038)

Complete medium: 1640 complete medium (article number: MD0201)

Gas phase: air, 95%; Carbon dioxide, 5%. Temperature: 37 ℃.

Freezing conditions: basic medium+5% DMSO+20% FBS

Complete cryopreservation solution: non-programmed cooling cell cryopreservation solution (low serum) (SD0001)

Note: This product is for scientific research only.

PubMed=305224; DOI=10.7326/0003-4819-88-3-323

Saxon A., Stevens R.H., Golde D.W.

T-lymphocyte variant of hairy-cell leukemia.

Ann. Intern. Med. 88:323-326(1978)

PubMed=6984393

Gauwerky C.E., Lusis A.J., Golde D.W.

Erythroid-potentiating activity: characterization and target cells.

Exp. Hematol. 8 Suppl. 8:117-127(1980)

PubMed=6987658; DOI=10.1073/pnas.77.1.593

Golde D.W., Bersch N., Quan S.G., Lusis A.J.

Production of erythroid-potentiating activity by a human T-lymphoblast cell line.

Proc. Natl. Acad. Sci. U.S.A. 77:593-596(1980)

PubMed=6600440; DOI=10.1007/BF02617996

Uittenbogaart C.H., Cantor Y., Fahey J.L.

Growth of human malignant lymphoid cell lines in serum-free medium.

In Vitro 19:67-72(1983)

Patent=US4438032

Golde D.W., Quan S.G.

Unique T-lymphocyte line and products derived therefrom.

Patent number US4438032, 20-Mar-1984

CLPUB00468

Javitt G.

Why not take all of me? Reflections on the immortal life of Henrietta Lacks and the status of participants in research using human specimens.

Minn. J. Law Sci. Technol. 11:713-755(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)